A保存的
发表于 2025-3-23 11:27:37
http://reply.papertrans.cn/29/2827/282679/282679_11.png
词汇
发表于 2025-3-23 17:55:56
http://reply.papertrans.cn/29/2827/282679/282679_12.png
Occlusion
发表于 2025-3-23 20:49:43
http://reply.papertrans.cn/29/2827/282679/282679_13.png
Plaque
发表于 2025-3-23 22:36:32
http://reply.papertrans.cn/29/2827/282679/282679_14.png
维持
发表于 2025-3-24 04:26:32
http://reply.papertrans.cn/29/2827/282679/282679_15.png
的事物
发表于 2025-3-24 09:20:33
http://reply.papertrans.cn/29/2827/282679/282679_16.png
推崇
发表于 2025-3-24 13:38:21
Jes Fenger,Ole Hertel,Finn Palmgrenity and efficacy monotonically increase with increasing dose. This is because the MTD is expected to produce maximal efficacy under admissible toxicity; thus, this dose is basically adopted as the optimal dose in the subsequent phase II and III trials. However, this paradigm is not necessarily suita
灯丝
发表于 2025-3-24 17:03:43
Olf Herbarth,Uwe Schlink,Matthias Richter This therapy can also be regarded as a type of biological therapy that uses substances made from living organisms to treat cancer, because it employs white blood cells and organs and tissues of the lymph system. Therefore, in cancer immunotherapy, determination of biologically optimal doses is crit
Blazon
发表于 2025-3-24 19:49:30
http://reply.papertrans.cn/29/2827/282679/282679_19.png
座右铭
发表于 2025-3-25 02:58:14
https://doi.org/10.1007/978-4-431-55585-8Adaptive Design; Cancer; Dose Finding; Phase I; Phase I/II